ipratropium albuterol Combivent Respimat
Selected indexed studies
- Efficacy and safety of ipratropium bromide/albuterol delivered via Respimat inhaler versus MDI. (Respir Med, 2010) [PMID:20172704]
- Combination of ipratropium bromide and salbutamol in children and adolescents with asthma: A meta-analysis. (PLoS One, 2021) [PMID:33621253]
- Drugs for COPD. (Med Lett Drugs Ther, 2020) [PMID:32960872]
_Worker-drafted node — pending editorial review._
Connections
ipratropium albuterol Combivent Respimat is a side effect of
Sources
- Anticholinergic bronchodilators. (1999) pubmed
- Drugs for COPD. (2020) pubmed
- Drugs for COPD. (2024) pubmed
- Drugs for asthma. (2020) pubmed
- Efficacy and safety of ipratropium bromide/albuterol delivered via Respimat inhaler versus MDI. (2010) pubmed
- Combination of ipratropium bromide and salbutamol in children and adolescents with asthma: A meta-analysis. (2021) pubmed
- Effect of Nebulized Magnesium vs Placebo Added to Albuterol on Hospitalization Among Children With Refractory Acute Asthma Treated in the Emergency Department: A Randomized Clinical Trial. (2020) pubmed
- Inhaled albuterol/salbutamol and ipratropium bromide and their combination in the treatment of chronic obstructive pulmonary disease. (2010) pubmed
- In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. COMBIVENT Inhalation Aerosol Study Group. (1994) pubmed
- Efficiency of Ipratropium Bromide and Albuterol Deposition in the Lung Delivered via a Soft Mist Inhaler or Chlorofluorocarbon Metered-Dose Inhaler. (2016) pubmed